You are here

  • Home
  • Archive
  • Volume 15, Issue 4
  • Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone

https://doi.org/10.1136/ebm1098

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests VF has received consultancy fees, lecture fees and grants from Glaxo Smith Kline, Novartis, Novo-Nordisk, Takeda, Astra-Zeneca, Sanofi-Aventis, Eli Lilly, Daiichi-Sankyo, Novartis, NIH, ADA. CD has received consultancy fees from Novo Nordisk and Takeda. ANK is an investigator in the TECOS trial funded by Merck.